Amedisys (NASDAQ:AMED – Get Rating) had its target price dropped by analysts at Truist Financial from $150.00 to $140.00 in a research note issued to investors on Wednesday, The Fly reports. Truist Financial’s price objective would indicate a potential upside of 38.72% from the company’s previous close.
Other analysts have also issued reports about the company. Jefferies Financial Group reaffirmed a “buy” rating and issued a $200.00 price objective on shares of Amedisys in a research note on Tuesday, June 28th. SVB Leerink dropped their target price on Amedisys from $117.00 to $107.00 and set a “market perform” rating for the company in a research report on Tuesday, June 21st. Royal Bank of Canada dropped their target price on Amedisys from $199.00 to $165.00 in a research report on Friday, July 29th. Stephens dropped their target price on Amedisys from $155.00 to $125.00 and set an “equal weight” rating for the company in a research report on Tuesday, June 21st. Finally, Cowen dropped their target price on Amedisys to $125.00 in a research report on Tuesday, August 9th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and ten have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Amedisys currently has an average rating of “Moderate Buy” and a consensus target price of $153.13.
Amedisys Stock Performance
AMED opened at $100.92 on Wednesday. The firm has a market cap of $3.27 billion, a P/E ratio of 23.52, a price-to-earnings-growth ratio of 2.39 and a beta of 1.01. Amedisys has a 52-week low of $95.33 and a 52-week high of $188.88. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.92 and a current ratio of 0.92. The business’s fifty day moving average is $117.40 and its 200-day moving average is $125.99.
Amedisys (NASDAQ:AMED – Get Rating) last released its earnings results on Wednesday, July 27th. The health services provider reported $1.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.23 by $0.24. The company had revenue of $557.89 million for the quarter, compared to analyst estimates of $583.12 million. Amedisys had a return on equity of 17.81% and a net margin of 6.33%. Amedisys’s quarterly revenue was down 1.1% on a year-over-year basis. During the same period in the prior year, the firm posted $1.69 EPS. Sell-side analysts expect that Amedisys will post 5.33 EPS for the current fiscal year.
Institutional Inflows and Outflows
Hedge funds have recently modified their holdings of the stock. Allworth Financial LP bought a new stake in shares of Amedisys during the 1st quarter valued at about $38,000. Northwestern Mutual Wealth Management Co. purchased a new stake in Amedisys during the 1st quarter valued at about $46,000. Covestor Ltd boosted its holdings in Amedisys by 88.9% during the 1st quarter. Covestor Ltd now owns 323 shares of the health services provider’s stock valued at $56,000 after acquiring an additional 152 shares during the period. Signaturefd LLC boosted its holdings in Amedisys by 295.8% in the first quarter. Signaturefd LLC now owns 376 shares of the health services provider’s stock valued at $65,000 after acquiring an additional 281 shares in the last quarter. Finally, First Horizon Advisors Inc. raised its position in shares of Amedisys by 862.5% in the 2nd quarter. First Horizon Advisors Inc. now owns 385 shares of the health services provider’s stock worth $40,000 after acquiring an additional 345 shares in the last quarter. Hedge funds and other institutional investors own 93.36% of the company’s stock.
About Amedisys
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Amedisys, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Amedisys wasn’t on the list.
While Amedisys currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Source: marketbeat.com
